Metoprolol Zot Stada

Metoprolol Tartrate, the active ingredient in Metoprolol Zot Stada, is a beta blocker presented as an oral dosage form for oral use. It is used to treat hypertension, angina pectoris, post‑myocardial infarction, heart failure and certain cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Zot Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Zot Stada acts on the cardiovascular system to control blood pressure and heart rhythm.

Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Angina pectoris: decreases frequency and severity of chest pain episodes. Post‑myocardial infarction: improves survival and reduces recurrence of ischemic events. Heart failure: diminishes mortality and hospital admissions by improving cardiac efficiency. Cardiac arrhythmias: controls ventricular rate and restores normal rhythm in atrial fibrillation and other tachyarrhythmias.

Metoprolol Zot Stada may cause a range of adverse reactions.

Common Side Effects: - Fatigue or tiredness. - Dizziness or light‑headedness. - Bradycardia (slow heart rate). - Cold extremities or peripheral vasoconstriction. - Mild gastrointestinal upset such as nausea. - Sleep disturbances or vivid dreams.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension. - Worsening heart failure. - Bronchospasm in patients with asthma or COPD. - Allergic reactions including rash, angioedema, or anaphylaxis. - Cardiogenic shock in rare cases.

Before prescribing Metoprolol Zot Stada, clinicians should consider several safety measures.

Assess cardiac function: evaluate baseline heart rate, blood pressure and ejection fraction. Monitor regularly: check vital signs and ECG after dose adjustments. Use caution in asthma/COPD: β1‑selectivity may still affect bronchial tone. Adjust for organ impairment: consider dose reduction in renal or hepatic dysfunction. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. Store at room temperature: keep in original packaging, protect from moisture and light.

Metoprolol Zot Stada can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant non‑selective beta blockers: risk of excessive β‑blockade. - Calcium channel blockers (verapamil, diltiazem): may cause profound bradycardia. - Potent CYP2D6 inhibitors (quinidine, fluoxetine): increase metoprolol plasma levels. - MAO inhibitors: potential for hypertensive crisis. - Clonidine withdrawal: can precipitate rebound hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: additive hypotensive effect. - Antidiabetic agents: mask hypoglycemia symptoms. - Thyroid hormones: may enhance tachycardia. - Digoxin: increased risk of atrioventricular block.